Q3 FY2026
Filed Nov 12, 2026Nuwellis cuts Q3 operating loss 24% on 430 bp gross margin expansion and 13% lower operating expenses, but Q3 net sales were flat year over year
Gross margin and operating loss improved and nine-month sales grew 13%, but Q3 net sales were unchanged versus a prior-year quarter that included a $0.4 million backorder, console unit sales in Q3 fell to 8 from 12, and Q3 net loss of $(1,969) thousand compared with net income of $468 thousand a year earlier, which included a warrant fair value gain.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net sales, Q3 2026 (three months ended Sept 30)GAAP | $2.21M | approximately 12% | – |
| Net sales, nine months ended Sept 30, 2026GAAP | $6.58M | – | 13% |
| Cost of goods sold, Q3 2026GAAP | $674K | – | – |
| Cost of goods sold, nine months ended Sept 30, 2026GAAP | $1.86M | – | – |
| Gross profit, Q3 2026GAAP | $1.54M | – | – |
| Gross profit, nine months ended Sept 30, 2026GAAP | $4.72M | – | – |
| Gross margin, Q3 2026GAAP | 69.5% | – | 430 basis points |
| Gross margin, nine months ended Sept 30, 2026GAAP | 71.7% | – | – |
| Selling, general and administrative expenses, Q3 2026GAAP | $3.01M | – | – |
| Research and development expenses, Q3 2026GAAP | $584K | – | – |
| Total operating expenses, Q3 2026GAAP | $3.59M | – | 13% reduction |
| Total operating expenses, nine months ended Sept 30, 2026GAAP | $14.51M | – | – |
| Loss from operations, Q3 2026GAAP | −$2.05M | – | 24% improvement |
| Loss from operations, nine months ended Sept 30, 2026GAAP | −$9.79M | – | – |
| Net (loss) income, Q3 2026GAAP | −$1.97M | – | – |
| Net loss, nine months ended Sept 30, 2026GAAP | −$11.34M | – | – |
| Basic and diluted (loss) income per share, Q3 2026GAAP | $(5.81) | – | – |
| Basic and diluted loss per share, nine months ended Sept 30, 2026GAAP | $(93.13) | – | – |
| Change in fair value of warrant liabilities, Q3 2026GAAP | $94K | – | – |
| Financing expense, nine months ended Sept 30, 2026GAAP | −$6.14M | – | – |
| Net cash used in operating activities, nine months ended Sept 30, 2026GAAP | −$9.27M | – | – |
| Aquadex consoles sold, Q3 2026other | 8 consoles | – | – |
| Aquadex consoles sold, nine months ended Sept 30, 2026other | 32 consoles | – | 88% increase |
| Pediatric net sales growth, Q3 2026 versus Q3 2025other | 20% increase | – | 20% |
| Pediatric net sales growth, nine months ended Sept 30, 2026 versus prior-year periodother | 26% increase | – | 26% |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| PediatricsThe release describes the pediatric segment as a significant growth driver and says the segment's net sales increased 20% in Q3 2026 and 26% year to date versus the prior-year periods. The release does not print the segment's dollar revenue. | Not disclosed in dollars in the release | – | 20% in Q3 2026; 26% year to date |
Capital returns
- The release reports no share repurchases or cash dividends.
- In July 2026 the company raised $3.4 million in gross proceeds in a direct offering.
- Concurrently, the company received $3.3 million in gross proceeds from the cash exercise of warrants.
- During Q3 2026 the company received $1.4 million in net proceeds from common shares sold under its ATM.
- Nine-month cash flow statement shows proceeds from issuance of common stock and warrants, net of $15,392 thousand and issuance of common stock from ATM, net of $1,358 thousand.
- Q3 2026 deemed dividend attributable to Series J Convertible Preferred Stock was $2 thousand.
What drove it
- Company explanation: Q3 2026 gross margin of 69.5% reflected increased average selling prices and benefits from the transition to contract manufacturing.
- Company explanation: the 13% reduction in operating expenses was primarily attributed to outsourced manufacturing efficiencies and efforts to align expenses with the highest-priority commercial and strategic programs.
- Company explanation: flat Q3 net sales were primarily due to a $0.4 million backorder fulfilled in Q3 2025.
- Company explanation: nine-month net sales growth was driven by growth in U.S. circuit and console sales.
- Company explanation: the Q3 2025 net income of about $0.5 million included a significant noncash gain associated with changes in the fair value of warrant liabilities.
- Console unit sales for nine months rose 88% to 32 consoles, which the company says expands the installed base for future recurring circuit revenue.
- Business updates: 510(k) submitted to expand the Aquadex indication to pediatric patients weighing five kilograms and above; co-promotion and distribution agreement with Atrility Medical for AtriAmp; second distribution agreement for the pediatric Zorro-Flow external urine collection system.
Concerns
- Q3 2026 net sales of $2,212 thousand were unchanged from $2,217 thousand in Q3 2025.
- Q3 2026 Aquadex console sales were 8 versus 12 in the prior-year quarter.
- Q3 2026 net loss of $(1,969) thousand compares with net income of $468 thousand in Q3 2025, which the release says included a warrant fair value gain.
- Nine-month financing expense was $(6,138) thousand and nine-month operating loss was $(9,790) thousand, larger than the prior-year $(8,663) thousand.
- Nine-month operating cash outflow was $(9,272) thousand versus $(7,780) thousand in the prior-year nine months.
- Nine-month total operating expenses rose to $14,510 thousand from $12,133 thousand, even as Q3 operating expenses fell.
- Cash on hand increased largely through equity and warrant financing in 2026, including a $3.4 million direct offering and $3.3 million of warrant exercise proceeds in July 2026.
What to watch
- FDA decision on the 510(k) submission to expand the Aquadex indication to pediatric patients weighing five kilograms and above.
- Console unit sales and whether the installed base translates into recurring circuit revenue in coming quarters.
- Q4 2026 net sales comparison, since the prior-year quarter's backorder effect will no longer be a factor in Q3.
- Whether gross margin gains and operating expense reductions continue, and the operating cash burn rate against the $8.3 million cash balance.
- Contribution of the Atrility Medical and Zorro-Flow distribution agreements to revenue.
- Continued use of equity and warrant financing, including ATM sales, to fund operations.
Balance sheet and cash flow
- Cash and cash equivalents: $8,290 thousand at Sept 30, 2026 versus $1,085 thousand at Dec 31, 2025. The release describes this as approximately $8.3 million.
- Total assets: $13,445 thousand at Sept 30, 2026 versus $6,118 thousand at Dec 31, 2025.
- Total liabilities: $3,589 thousand at Sept 30, 2026 versus $3,488 thousand at Dec 31, 2025.
- Total stockholders' equity: $9,845 thousand at Sept 30, 2026 versus $2,624 thousand at Dec 31, 2025.
- Net cash used in investing activities, nine months 2026: $(271) thousand versus $(102) thousand in the prior-year nine months.
- Net cash provided by financing activities, nine months 2026: $16,750 thousand versus $5,888 thousand in the prior-year nine months.
- Cash paid for the acquisition of Rendiatech, net of cash acquired, was $(164) thousand in the nine months; deferred consideration from the Rendiatech acquisition totals $113 thousand current and $200 thousand non-current on the balance sheet.
- Restricted cash at Sept 30, 2026 was $107 thousand; cash and restricted cash at period end were $8,397 thousand.
Analysis
Nuwellis reported third-quarter 2026 net sales of $2,212 thousand, essentially unchanged from $2,217 thousand in the prior-year quarter, which the company attributes to a $0.4 million backorder fulfilled in Q3 2025. Sequentially, the release states net sales increased approximately 12% from Q2 2026, but does not print the Q2 figure. For the nine months, net sales rose 13% to $6,584 thousand from $5,846 thousand, and the release attributes this to growth in U.S. circuit and console sales. Pediatric net sales grew 20% in Q3 and 26% year to date, and the company describes pediatrics as a significant growth driver. The release does not print pediatric dollar revenue.
Margins improved. Q3 gross margin was 69.5% versus 65.2%, a 430 basis point gain the company attributes to higher average selling prices and its contract manufacturing transition. Nine-month gross margin was 71.7% versus 59.4%. Q3 cost of goods sold fell to $674 thousand from $772 thousand and gross profit rose to $1,538 thousand from $1,445 thousand.
Cost discipline is visible in Q3 operating expenses, which fell to $3,591 thousand from $4,142 thousand, a 13% reduction that the company attributes to outsourced manufacturing efficiencies and alignment of spending to priority programs. Loss from operations narrowed 24% to $(2,053) thousand from $(2,697) thousand. On a nine-month basis, however, operating expenses rose to $14,510 thousand from $12,133 thousand and operating loss widened to $(9,790) thousand from $(8,663) thousand, with R&D of $3,254 thousand against $1,828 thousand in the prior-year nine months. The release does not provide a nine-month R&D explanation beyond the Rendiatech acquisition, which appears in the cash flow statement as a $757 thousand non-cash IP R&D charge.
Below the operating line, Q3 net loss was $(1,969) thousand against net income of $468 thousand in Q3 2025. The prior-year figure included a warrant fair value gain of $3,161 thousand, and Q3 2026 warrant fair value change was $94 thousand. Nine-month net loss narrowed to $(11,338) thousand from $(15,099) thousand, helped by lower financing expense of $(6,138) thousand against $(10,553) thousand. Basic and diluted loss per share was $(5.81) in Q3 2026 against $177.16 of income per share in Q3 2025, reflecting a much larger share count of 338,384 thousand weighted shares in Q3 2026 versus 2,646 thousand a year earlier.
Cash and equivalents were $8,290 thousand at Sept 30, 2026, up from $1,085 thousand at Dec 31, 2025, mainly reflecting $16,750 thousand of nine-month financing inflows. Operating cash use widened to $(9,272) thousand from $(7,780) thousand for the nine months. The company issued shares and warrants in July 2026 through a $3.4 million direct offering and received $3.3 million from warrant exercises, and it received $1.4 million net from ATM sales in Q3. The release provides no guidance for future periods, so the outlook rests on the business updates: the Aquadex pediatric 510(k) submission, the Atrility Medical co-promotion agreement, and the Zorro-Flow distribution agreement.
Management, verbatim
Although our third quarter faced a tough comparison against the prior-year period when we fulfilled a significant backorder, the underlying momentum in our business remains strong, as evidenced by the growth in our pediatric segment,
Mike McCormick, President and Chief Executive Officer, Nuwellis
Further, by expanding gross margins and maintaining disciplined cost management, we significantly narrowed our operating loss and cash use during the quarter while continuing to invest in the areas that matter most to our long-term growth.
Mike McCormick, President and Chief Executive Officer, Nuwellis
Not in the filing
stated, not guessed- Company financial guidance for future periods (none provided in the release).
- Consensus estimates or analyst expectations (not in the documents).
- Share price reaction (not in the documents).
- Q3 2025 year-over-year percentage change for net sales (release says unchanged, no percentage printed).
- Prior-quarter (Q2 2026) net sales in dollars (release gives only approximately 12% sequential change).
- Pediatric segment revenue in dollars for Q3 2026 and nine months 2026.
- Quarter-over-quarter figures for gross margin, operating expenses, operating loss and net loss.
- Year-over-year percentage changes for Q3 cost of goods sold, gross profit, SG&A, R&D and net loss.
- Year-over-year percentage change for nine-month gross margin (only levels printed).
- Year-over-year percentage change for nine-month operating expenses and operating loss (only levels printed).
- Prior-period comparisons for Q3 consoles sold as a percentage change.
- Adjusted or non-GAAP measures (none reported).
- Operating income, EBITDA or free cash flow reconciliations (not reported).
- Quarter-end cash balance for June 30, 2026 (not printed).
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.